

Contents

Abbreviations.....	15
Abstracts.....	25
Abstract	25
Resumen.....	26
Resum.....	28
1. Introduction.....	33
1.1. The heart	33
1.1.1. Cardiac tissue: structure and function	33
1.1.2. Resident cells in the myocardium	35
1.2. Cardiac metabolism: Role of fatty acids in the heart	37
1.2.1. Cardiac mitochondrial metabolism	39
1.2.2. Signal transduction in cardiomyocytes.....	41
1.2.3. Post-translational modifications.....	41
1.3. Acute myocardial infarction	42
1.3.1. Epidemiology	42
1.3.2. Pathophysiology	42
1.3.3. Underlying molecular mechanisms of cardiomyocytes death during I/R-induced injury	46
1.3.4. Dynamics of fibroblast activation during AMI	49
1.4. Diagnosis and conventional treatments of AMI.....	50
1.5. Advanced therapies for AMI.....	51
1.5.1. Nanotechnology and polymer-drug nanoconjugates.....	53
1.5.2. Cell therapy based on the use of MSC.....	57
1.6. Cellular communication mechanisms.....	61
1.6.1. Extracellular vesicles.....	62
1.6.2. Soluble factors: Oncostatin-M.....	68
2. Hypothesis and objectives.....	76
3. Methodology	79

3.1. Cellular models.....	79
3.1.1. Prokaryote cell types.....	79
3.1.2. Eukaryotic primary cultures and cell lines.....	79
3.2. Cell culture.....	82
3.2.1. Cells thawing.....	82
3.2.2. Cell expansion.....	82
3.2.3. Cell cryopreservation.....	82
3.2.4. Cell viability counting.....	83
3.2.5. Cardiomyocytes differentiation from iPSC.....	83
3.3. Molecular genetics techniques.....	84
3.3.1. Bacterial transformation and amplification.....	87
3.3.2. Isolation and purification of plasmid DNA from bacteria.....	88
3.3.3. Enzymatic digestion.....	88
3.3.4. Lentiviral transduction and engineered MSC lines generation.....	89
3.3.5. Large scale transfection in Expi293F cells.....	90
3.4. SEV isolation from cell culture supernatants.....	91
3.4.1. SEV production medium.....	91
3.4.2. SEV isolation.....	92
3.5. Molecular biology techniques.....	92
3.5.1. RNA purification and quantification.....	92
3.5.2. Reverse transcription and Real Time PCR.....	93
3.5.3. Reverse transcription: cDNA synthesis.....	93
3.5.4. Relative quantification of gene expression by real time quantitative PCR	93
3.5.5. qPCR results analysis.....	95
3.6. Biochemical techniques.....	95
3.6.1. Extraction of protein content.....	95
3.6.2. Protein quantification assay.....	96
3.6.3. Polyacrylamide gel electrophoresis.....	97

3.6.4.	Protein transfer by Western Blot assay.....	98
3.6.5.	Membrane blocking, antibody labelling and signal detection	98
3.7.	Immunocytochemistry.....	100
3.8.	Imaging techniques	101
3.8.1.	Fluorescence optical microscopy	101
3.8.2.	Time-lapse microscopy	101
3.8.3.	Confocal microscopy.....	102
3.8.4.	IN Cell.....	102
3.8.5.	Transmission electron microscopy (TEM)	103
3.9.	Cytomics	104
3.10.	SEV quantification.....	105
3.10.1.	Nanoparticle tracking analysis.....	105
3.10.2.	SEV protein quantification.....	105
3.11.	Ischemia-reperfusion <i>in vitro</i> model	105
3.12.	Chemicals and Nanoconjugates.....	105
3.13.	Functional <i>in vitro</i> assays.....	106
3.13.1.	Cytotoxicity assays.....	106
3.13.2.	Internalization assays	107
3.13.3.	Apoptosis assays.....	108
3.13.4.	Reactive oxygen species generation measurement.....	110
3.13.5.	Autophagy and endoplasmic reticulum stress study	110
3.13.6.	Mitochondria integrity tests.....	111
3.13.7.	Migration and proliferation assays.....	112
3.13.8.	Fibrosis stimulation	114
3.14.	<i>In vivo</i> studies	114
3.14.1.	Ischemia/Reperfusion <i>in vivo</i> models.....	115
3.14.2.	Cardiac magnetic resonance	118
3.15.	Histological Techniques	119
3.15.1.	Tissue collection and staining.....	119

3.16. Statistics.....	120
4. Results	124
Section A: PGA-diDHA-based nanoconjugates role in cardiomyocytes pre-conditioning during ischemia-reperfusion induced injury.	
125	
4.1. Human coronary microvascular endothelial cells, Neonatal Rat Cardiomyocytes and Neonatal Rat Cardiac fibroblasts characterization	125
4.2. Half maximal inhibitory concentration in HMVEC-C, NRVM and cFib depends on nanoconjugates diDHA loading and encapsulation.....	126
4.3. PGA-diDHA-based nanoconjugates uptake evaluation in HMVEC-C, NRVM and cFib	128
4.4. Oxygen and glucose deprivation and reperfusion protocol <i>in vitro</i>	129
4.4.1. PGA-diDHA-based nanoconjugates reduce Caspase 3/7 activity after I/R-induced injury	130
4.4.2. PGA-diDHA nanoconjugates uptake depends on the physiological conditions of HMVEC-C and NRVM	132
4.4.3. NRVM uptake PGA-diDHA-based nanoconjugates from HMVEC-C more efficiently under I/R conditions	134
4.4.4. PGA-diDHA _{6.4} limits I/R-induced injury by reducing apoptosis in NRVM	136
4.4.5. PGA-diDHA nanoconjugates treatment attenuates autophagy activity in NRVM after I/R-induced injury	139
4.4.6. PGA-diDHA-based nanoconjugates reduce reactive oxygen species generation and restore the I/R-induced loss of mitochondrial membrane potential in NRVM	142
4.5. PGA-diDHA-based nanoconjugates do not promote cFib migration <i>in vitro</i>	147
4.6. PGA-diDHA _{6.4} exerts a cardioprotective effect in human iPSC-derived CM	149
4.7. PGA-diDHA _{6.4} ameliorated myocardial injury in a small animal model if I/R-induced injury	153
4.8. Ischemic zone pre-conditioning with PGA-diDHA _{6.4} before reperfusion reduces area at risk after AMI in a large animal of I/R-induced injury	156

Section B: Oncostatin-M-enriched SEV isolated from genetically modified MSC as potential anti-fibrotic agent..... 160

4.9. OSM receptors LIFR, GP130 and OSMR gene expression is changed upon cardiac ventricular fibroblasts stimulation..... 160

4.10. OSM reduced human cardiac ventricular fibroblasts proliferation and activation upon fibrosis stimulation *in vitro*..... 163

4.11. rhOSM interferes with proliferation and migration capabilities of MSC from dental pulp origin..... 165

4.12. OSM native sequence fusion to lactadherin for specific anchoring in MSC derived SEV fails to load the protein of interest 168

4.12.1. Engineered MSC lines characterization 168

4.12.2. Doxycycline addition to engineered MSC affects cell viability and proliferation rate 170

4.12.3. SEV isolated from engineered MSC conditioned media maintain characteristic EV markers content, expected morphology and same size distribution 173

4.12.4. OSM is not detected in SEV isolated from engineered MSC conditioned culture media after constructs expression induction with doxycycline 176

4.13. OSM sequence modification is necessary in order to anchor it to SEV surface proteins..... 178

4.13.1. OSM is loaded in Expi293F derived SEV after cell transduction with modified sequences of the protein 178

4.13.2. Mutant and Mature OSM showed functional activity in human cardiac ventricular fibroblasts 183

4.14. Mutant and Mature OSM variants loaded in SEV isolated from Engineered Immortalized MSC suggest an enhanced therapeutic potential effect against fibrosis 193

4.14.1. Immortalized MSC genetic modification for CD81, matureOSM-CD81 and mutantOSM-CD81 fusion proteins specific loading in SEV surface 193

4.14.2. matureOSM-CD81 and mutantOSM-CD81 fusion proteins are detected on SEV..... 196

4.14.3. OSM loaded on SEV affects NHCF-V proliferation under starving conditions and telo-Col1 α 1 protein location after stimulation.....	198
5. Discussion	204
Section A: PGA-diDHA-based nanoconjugates role in cardiomyocytes preconditioning during ischemia-reperfusion induced injury.....	205
Section B: Oncostatin-M-enriched SEV isolated from genetically modified MSC as potential anti-fibrotic agent.....	210
6. Conclusions.....	218
7. Bibliography.....	222